Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs

October 20, 2021 Auto Bot Biotech, CRISPR 0

Shots:

  • Beam to receive $50M up front & is eligible to receive a target option exercise fees, milestones upon achievement of development & sales milestones along with royalties on sales of products
  • The agreement will combine Beam’s gene-editing technology with Sana’s ex vivo platform to use the Cas12b system for ex vivo engineered cell therapy programs
  • Sana gets a non-exclusive right to use Beam’s Cas12b system with allogeneic T cell & stem cell-derived programs & can make gene edits for Sana’s hypoimmune platform. Cas12b is a CRISPR-based nuclease with a high degree of specificity & efficiency which can be used to knock out & knock-in genes in certain cell types

Click here to­ read the full press release/ article | Ref: Globe Newswire | Image: Holdereauz Studio

The post Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs first appeared on PharmaShots.